**Objective:** In the present study we analyzed neuroprotective and antiapoptotic effect of the difumarate salt S-15176, as an anti-ischemic, an antioxidant and a stabilizer of mitochondrial membrane in secondary damage following spinal cord injury (SCI) in a rat model.

**Methods:** Three groups were performed with 30 Wistar rats: control (1), trauma (2), and a trauma+S-15176 (10 mg/kg i.p., dimethyl sulfoxide) treatment (3). SCI was performed at the thoracic level using the weight-drop technique. Spinal cord tissues were collected following intracardiac perfusion in 3rd and 7th days of posttrauma. Hematoxylin and eosin staining for histopathology, terminal deoxynucleotidyl transferase dUTP nick end labeling assay for apoptotic cells and immunohistochemistry for proapoptotic cytochrome-c, Bax and caspase 9 were performed to all groups. Functional recovery test were applied to each group in 3rd and 7th days following SCI.

**Results:** In trauma group, edematous regions, diffuse hemorrhage, necrosis, leukocyte infiltration and severe degeneration in motor neurons were observed prominently in gray matter. The number of apoptotic cells was significantly higher (p<0.05) than control group. In the S-15176-treated groups, apoptotic cell number in 3rd and 7th days (p<0.001), also cytochrome-c (p<0.001), Bax (p<0.001) and caspase 9 immunoreactive cells (p<0.001) were significantly decreased in number compared to trauma groups. Hemorrhage and edema in the focal areas were also noticed in gray matter of treatment groups. Results of the locomotor test were significantly increased in treatment group (p<0.05) when compared to trauma groups.

**Conclusion:** We suggest that difumarate salt S-15176 prevents mitochondrial pathways of apoptosis and protects spinal cord from secondary injury and helps to preserve motor function following SCI in rats.

**Key Words:** Difumarate salt (S-15176) · Spinal cord Injury · Cytochrome-c · Caspase-9 · Apoptosis.

---

**INTRODUCTION**

Spinal cord injury (SCI) can occur as a consequence of various injuries such as car accidents, falls or gunshot injuries. Traumatic SCI represents a serious medical and scientific challenge, being the cause of permanent neurological deficits and disabilities. Damage to the spinal cord is not only limited to the initial injury but may also continue with the secondary damage. At the present day, it appears to be impossible to treat primary damage leading to irreversible injury. After centuries of observing the catastrophic consequences of SCI, the conception of secondary damage defined by Allen was about to give hope for newly developed medical solutions.

It is well known that cells can die in two mechanisms: necrosis and apoptosis. Primary injury caused by mechanical tissue damage results in necrotic cell death whereas secondary injury is the terminal of a cascade of events triggered by activation of cell death mechanisms. On this account, most of the experimental and clinical studies have focused on preventing secondary damage. Secondary injury process include edema, hemorrhage, inflammatory reaction, ischemia, the disruption of energy metabolism. Increased glutamate levels, excitotoxicity, oxidative stress, ischemia, Ca(2+)-dependent production of nitric oxide, damage to cell membrane caused by free radicals and lipid peroxidation are some of the major components in secondary injury process. Apoptosis is an actively regulated response that occurs after various cells have been subjected to external or internal stimuli. For quite some time, it has been well demonstrated that
spinal cord lesions are greatly exacerbated by apoptosis as a result of secondary damage. Early experiments have shown that mitochondria plays a pivotal role in SCI through apoptosis. Mitochondria is the check point of the pathways like death receptors, granzymes, genomic damage etc. which play role in apoptosis. Cell death as a consequence of damage has been shown to involve bax translocation to and cytochrome-c (cyt-c) release from the mitochondria, followed by caspase-3 and subsequently caspase-9 activation. This event is characterized by fragmentation of DNA and nuclear morphological changes. Cyt-c, a component of the electron transport system, has been demonstrated to be essential in both intact cell and cell-free systems of apoptosis. The increase in intracellular oxygen radicals, decrease in ATP/ADP and NADPH levels, transcription and translation errors of Bcl-2 and damage of DNA breakdown the permeability of the mitochondria membrane. The reduction in electrochemical gradient of mitochondria transmembrane potential (ΔΨm) gives rise to the membrane permeability. Thus, damage to mitochondria activates different signaling pathways and cyt-c and apoptosis inducing factor (AIF) are released from the inner membrane of mitochondria and participate in effector phase of apoptosis. Changes in permeability triggered by calcium are observed in cellular death. These changes exacerbate osmotic swelling and mitochondrial lysis by reducing mitochondrial membrane potential (MMP) . S-15176 interacts with several targets in mitochondria.

**MATERIALS AND METHODS**

All experiments were conducted according to the NIH Guide for the Care and Use of Laboratory Animals after approval by the Ethics Committee for Animal Experiments of Istanbul University.

**Anesthesia and animal preparation**

Thirty adult male Wistar type albino rats were used. They were fed a normal diet throughout the study period and weighed 220–340 g. All the rats were starved for 24 hours before the operation. Induction of anesthesia was made by the intramuscular application of 60 mg/kg ketamine (Ketalar, Parke-Davis, Eczacibasi, Istanbul, Turkey) and 9 mg/kg Xylazine (Rompun, Bayer, Istanbul, Turkey). When necessary, 20% of the initial dose was repeated intermittently.

**Surgical procedure**

Dorsal regions of the animals were shaved and cleaned with antiseptic solution (Poviodeks, KIM-PA, Istanbul, Turkey) after the anesthesia. In prone position a 25 to 30 mm midline incision was made using interscapular distance as a reference point. T6, T7, and T8 laminae were exposed by blunt dissection and separation of paravertebral muscles laterally. Total laminectomies were performed at three levels with a micro ronguer under a microscope (Karl Zeiss OPMI Vario 888, Oberkochen, Germany). Dura mater was kept intact through the procedure. Body temperature was monitored throughout the operation and maintained at 37°C with heating pads until the end of the anesthesia. Through further steps different procedures were applied to each group.

**Spinal cord injury**

SCI was performed via the drop-weight technique developed by Allen. Laminctomies were applied to set front the dura mater. Afterwards, a 5 mm diameter cylindrical glass tube was positioned at a 90° angle to the dorsal surface of the dura mater. A 4-g weight was dropped from a height of 10 cm through the tube onto the exposed spinal cord.

**Experimental protocol**

Animals were randomly divided into 3 groups of 10.

**Group I (n=10, sham-operated control group)**

In this group, total laminectomies were applied at thoracic 6–8 levels, and then the wound was closed. On the third day after surgery, five animals were perfused with 10% formaldehyde transcardially. After the rats were killed, the surgical zone was opened again and tissues were collected under microscope. On the seventh day, the same procedure was followed in the remaining 5 rats after the evaluation of neurologic status.

**Group II (n=10, trauma control group)**

Laminectomies were applied to the animals as described in first group and SCI was produced in the aforementioned manner. After trauma, rats were treated with Dimethylsulfoxide (DMSO) intra-peritoneally in an equivalent dose to that of S-15176. Exactly as described for Group I, the functional recovery of the animals were assessed, spinal cord samples were collected and processed at the third and seventh days postinjury.
Group III (n=10, S-15176 treatment group)

The same surgical and trauma procedures in Group II were performed to each rat in this group. S-15176 (Sigma; Farmakim, Istanbul, Turkey) was dissolved in DMSO, and administered (10 mg/kg, ip) just after weight drop trauma. Tissue collection and functional assessment are described above.

The animals were protected in a temperature-controlled room (26–28°C) for 3 days, one per cage. Bladders were manually expressed three times per day. All animals were killed by decapitation 72 h after SCI.

Light microscopy-histopathology

Tissue samples were divided into three portions and each one-third part was used for light microscopic evaluation, immunohistochemistry and TUNEL staining. Spinal cord tissues obtained at 3rd and 7th days postinjury were defined by 10% neutral formalin solution and each 2-cm cord segment was embedded in paraffin 5 µm thick coronal sections were taken and put on microscope slides covered with poly-l-lysine (PLL, Sigma P-8920, St. Louis, MO, USA). They were stained with hematoxylin and eosin (H and E), and cresyl violet (CV) dyes for histopathological evaluation. Slides were examined under the light microscope at 400× magnification.

Immunohistochemistry

Immunohistochemical analysis was performed as previously described. Immunoperoxidase staining was performed using Histostain-Plus Bulk Kits (Life Technologies, 85-9043, GrandIsland, NY, USA), including rabbit polyclonal Bax (Delta Biolabs. DB005, Muraoka Drive Gilroy, CA, USA; 1 : 50 dilution), goat polyclonal cytochrome-c (Santa Cruz Biotechnology, sc-8385, Santa Cruz, CA, USA; 1 : 50 dilution) antibodies and rabbit polyclonal active caspase-9 antibodies (Novus Bio., NB100-56118, Littelton, USA; 1 : 500 dilution). Immunostaining procedures were carried out following the manufacturer's instructions. To determine the specificity of immunostaining, sections were incubated following the above procedure except for omission of incubation with the primary antibody. Instead of primary antibody, control serum was used as negative control.

Semiquantitation of immunoperoxidase staining

Immunostaining was evaluated using a Leica DM2500 light microscope (Leica Microsystems, Wetzlar, Germany). Bax, cytochrome-c and caspase-9 immunostainings were analyzed in the immunoperoxidase stained cord tissues in randomly selected areas. The blind and randomized mode of analysis was performed at ×400 magnification for all immunoperoxidase stained sections in per cord section. All animals were included in the data analysis.

The TUNEL staining and quantification of apoptotic cells

TUNEL method was used to detect apoptotic cells in spinal cord samples that were collected at 3rd and 7th days postsurgical/injury. The in situ DNA end making method was used and it was conducted according to the protocol provided in the kit (ApopTag Plus, In Situ Apoptosis Detection Peroxidase kit, S7101-KIT, Chemicon). TUNEL analysis was performed as previously described. For staining specificity controls, the thymus tissue of dexametazone-treated rat was used as positive control. Distilled water was used instead of Tdt enzyme as a negative control. Cells with brown nuclear labeling were defined as TUNEL positive. Staining was evaluated using a light microscope after counterstaining with methyl green.

Apoptotic index

Marked apoptotic cells were counted under high-powerfields (×400) with a light microscope. Nuclei stained with methyl green were evaluated as healthy while cells with Brown nuclear staining were considered TUNEL positive. All TUNEL positive cells in 12 different unit areas were counted on the cross-sections by a blinded researcher. These 12 fields were randomly selected from slides without discrimination between white and gray matter. Average cell per unit area number for each set of specimens (3 days and 7 days) in each group was calculated and compared.

Evaluations of motor function

BBB Scale developed by Basso et al. is a semi-quantitative scale evaluates movement, weight support and coordination of the rats. The results were evaluated according to this scale, where 0 indicates no motor activity and 21 indicates normal performance. Open field BBB scoring was applied to the animals at 3 days and 5 days after surgery/injury. Two researchers who were blinded to experimental protocols evaluated the functional recovery. Animals were allowed to walk freely in a 75 ×120 cm field where the movements of the hind limbs were closely observed and their ability to maintain postural stability was assessed with inclined-plane test.

Statistical analysis

Values were expressed as mean±SD. Statistical analysis for cytochrome-c, bax, caspase-9 immunoreaction and apoptotic cell number after the normality of variables was checked. The Kruskall-Wallis test was used and subsequently Mann-Whitney U non-parametric test was performed for significant data obtained in the Kruskall-Wallis test. p<0.05 was considered as statistically significant.

RESULTS

Histopathologic findings

Edema, hemorrhage, necrosis and leukocyte infiltration were evaluated through histological examination. Light microscopic examination of the neural and vascular structure of cord samples revealed normal findings in control groups (Fig. 1A). Cross-sections obtained at third and the seventh days posttrauma,
showed diffuse hemorrhage, cavitation, necrotic, and edematous areas especially in the gray matter. The traumatized cord segment also showed degeneration in motor neurons (Fig. 1B, C). In the specimens of the seventh day trauma group, there were hemorrhagic areas in white and gray matter, necrosis, edema and cavitation (Fig. 1C). S-15176-treated group showed more healthy cells in gray matter beside cavitation areas, hemorrhagic and edematous regions on the third day (Fig. 1D). In the seventh day of the S-15176-treated group, the cord samples revealed less cavitation and demyelinization of nerve fibers and increased number of healthy cells when compared to other groups (Fig. 1E).

**Bax immunohistochemical staining**

In all tissue cross-sections, Bax immunopositivity was count-
ed by scanning of the gray and white matter. Bax immunopositivity was observed in very small proportion of cells in control group (Fig. 2A). A large number of glial cells and motor neurons have shown immunopositivity for Bax in trauma third day group (93.8±9.98) (Fig. 2B). More immunopositive cells were counted in trauma seventh day compared to the trauma third day (108.0±15.28) (Fig. 2C). Decreased Bax immunopositivity was observed in the third day of the treatment with S-15176 (52.0±19.00) (Fig. 2D). Significantly less Bax immunopositive glial cells and motor neurons were counted in the seventh day of S-15176-treatment compared to trauma groups and third day S-15176-treated group (30.8±8.33) (p<0.001) (Fig. 2E).

Fig. 3. Cytochrome-c immunostaining of spinal cord tissue samples. Control (A), trauma 3rd day (B), trauma 7th day (C), S-15176-treated 3rd day (D), S-15176-treated 7th day (E) groups (bar : 20 µm). Evaluation of cytochrome-c immunopositive cell numbers in the trauma groups; *p<0.01 vs. trauma 3rd, †p<0.001 vs. trauma 7th, ‡p<0.001 vs. trauma 3rd days.

Fig. 4. Caspase-9 immunostaining of spinal cord tissue samples. Control (A), trauma 3rd day (B), trauma 7th day (C), S-15176-treated 3rd day (D), S-15176-treated 7th day (E) groups (bar : 20 µm). Evaluation of caspase-9 immunopositive cell numbers in the trauma groups: *p<0.01 vs. trauma 3rd and †p<0.001 vs. trauma 7th days.
Cytochrome-c immunohistochemical staining
Cytoplasmic cytochrome-c immunopositivity was evaluated in all tissue cross-sections at all gray and white matter. Weak (-) cyt-c immunopositivity was observed in the control group (Fig. 3A). In trauma third day group, immune positive cells for cyt-c were significantly increased in motor neurons and glial cells (45.2±9.91) (Fig. 3B). More cyt-c immunopositivity was seen in the trauma seventh day group when compared to other groups (95.8±9.65) (p<0.001) (Fig. 3C). Decreased cyt-c immunopositivity was observed in the third day of the S-15176-treated group in all cross-section areas (29.4±6.87) (p<0.001) (Fig. 3D). This reduction was significant statistically in the seventh day of the S-15176 treated group, a significant decrease in caspase-9 immunopositive cell number was observed compared to trauma seventh day and S-15176-treated third day groups (1.77±0.25) (p<0.001) (Fig. 3E).

Caspase-9 immunohistochemical staining
Caspase-9 immunopositivity was evaluated in all tissue cross-sections at all gray and white matter. Weak (-) caspase-9 immunopositivity was observed in the control group (Fig. 4A). Immunopositivity for caspase-9 was increased in trauma third day group compared to control group (3.80±0.21) (Fig. 4B). In the trauma seventh day group immunopositivity was increased when compared to other groups (4.92±0.16) (p<0.001) (Fig. 4C). Caspase-9 immunopositivity was significantly decreased in the third day of the S-15176-treated group in all cross-section areas (2.50±0.18) (p<0.001) (Fig. 4D). In the seventh day of the S-15176-treated group, a significant decrease in caspase-9 immunopositive cell number was observed compared to trauma seventh day and S-15176-treated third day groups (1.77±0.25) (p<0.001) (Fig. 4E).

Apoptotic cell count
Cells with brown coloured nuclei were evaluated as apoptotic in the TUNEL staining method. Apoptotic cells were counted by scanning whole gray and white matter. Apoptotic cell number per unit area was found to be (0.08±0.0) in control group (Fig. 5A). Apoptosis was commonly observed near the lesion site among mostly the oligodendrocytes and other glial cells in trauma groups (Fig. 5B, C). The number of apoptotic cells per unit was (2.20±0.62) in trauma third day group and the increase was significant when compared to control groups (p<0.05). In the trauma seventh day group, apoptotic cell number per unit area was found to be (4.63±1.16). In the S-15176 treatment groups, apoptotic cell numbers in 3rd and 7th days were significantly decreased compared to 7th days of trauma group (2.08±0.34) (1.98±0.50) (p<0.001) (Fig. 5D, E).
Results of functional neurological improvement

Evaluation of the functional recovery by open field BBB scoring revealed the scores (1.20±0.83) and (1.20±0.83) for the trauma third day group and trauma seventh day trauma group respectively. BBB score was (1.40±0.54) for the third day of S-15176 treated group and (3.80±0.83) for the seventh day of S-15176 treatment. These results indicate significant recovery for the seventh day of S-15176 treated group compared to trauma groups and third day of S-15176 treated group (p<0.05) (Fig. 6).

DISCUSSION

Interest in regeneration studies on SCI has gained momentum in the last two decades since Cheng et al. have demonstrated that there could be regeneration in spinal cord after injury. Moreover, experimental studies have shown that a small aliquot of axonal residue could support neurological improvement. For this reason, any attempt to increase the number of functional cells and response to stimuli must be considered as a lead for possible recovery.

In 1996 Katoh et al. have shown apoptosis following the contusion of spinal cord after trauma. Apoptosis in neurons, astrocytes, oligodendroglialas and microglias of rats after SCI has been reported by Yong et al. and Liu et al. who were able to determine apoptosis in neurons and glia within 4 h after trauma. It has been demonstrated that apoptosis reaches its most intense point in neurons and glial cells on the 8th and 24th hours, respectively. It has also been stated that enlargement of the initial lesion was observed with more cell death and cavitation. Axon degeneration in oligodendrocytes in white matter on the seventh day revealed a second wave of apoptosis. In the trauma group of our study: edematous areas, diffuse hemorrhage, necrosis, cavitation and leukocyte infiltration were evaluated through histological examination especially in gray matter. The number of apoptotic cells had increased significantly near the lesion site and mitochondrial membrane permeability, it has also been reported that cyclosporine shows neuroprotective effects by inhibiting mitochondrial membrane permeability, it has also been reported that it could be important for preventing cell death in experimental traumatic cord injury studies. It has been suggested that opening of the mPTP causes a massive swelling of mitochondria coupled with collapse of the MMP, total inhibition of ATP synthesis, finally leading to cell death. A growing body of evidence suggests that viability of the cell would depend on the degree of PTP opening in this process. Ca2+ overload, high phosphate concentrations, ATP and ADP depletion and oxidative stress give rise to PTP opening. In isolated mitochondria, sustained mPTP opening and cyt-c release can be evoked by Ca2+ overload. A key component of the mitochondrial electron transport system, cyt-c is needed for the vitality of the cell, and as a key trigger of the mitochondrial route of apoptosis. The blockade of permeability transition prevents apoptotic neuregeneration and, consequently, suggests a potential strategy for neuroprotection. This is why a group of scientists have suggested that pore opening might be a critical event in the genesis of the cell death. Breakdown of MMP occurs as a result of intracellular changes after SCI. Consequently different pathways of cell death are activated. PTP is also thought to be a key factor in the release of the apoptosis-inducing factors and the activation of caspases.

Observations on Cyclosporine A have also reinforced this hypothesis. Cyclosporine A has been proposed as the most potent inhibitor of PTP, and it has been reported to be a protective agent which acts by inhibiting PTP. It has been suggested that cyclosporine shows neuroprotective effects by inhibiting mitochondrial membrane permeability. It has also been reported that it could be important for preventing cell death in experimental traumatic cord injury studies. Morin et al. have reported that search for novel PTP inhibitors should be considered with great interest, for molecules which can inhibit PTP opening can provide protection against reperfusion injury.

Trimetazidine has been shown to limit the extent of cellular injuries in experimental models of ischemia-reperfusion. This effect was thought to be due to the preservation of mitochondrial functions. Elimani et al. have investigated the neuroprotective effects of S-15176, Difumarate Salt which is a derivative of trimetazidine. It is thought that S-15176 inhibits mitochondrial permeability transition, prevents the early step in apoptosis by preventing collapse of the electrochemical gradient across the mitochondrial membrane. Settaf et al. have shown its membrane-stabilizing potential and anti-apoptotic effects on liver injury by using a rat model. It was clearly evident that S-15176 protected hepatocytes from ischemic injury and future studies would focus on mitochondrial pathways. However, it has been stated that present data did not provide detailed information on the mechanism of action. Uncertainty was resolved by...
a several of studies. Elimadi et al.\textsuperscript{15} have investigated the effects of S-15176 on mitochondrial functions by isolating mitochondria after ischemia reperfusion injury of liver. They have reported that S-15176 shows its effects on inner membrane and protects mitochondria by preventing passage of PTP. It has been demonstrated that S-15176 inhibits Adenine Nucleotide Translocase which regulates ADP/ATP exchange on mitochondrial membrane and is able to prevent PTP opening also in this way\textsuperscript{19}. Morin et al.\textsuperscript{30} have shown that S-15176 inhibits the mitochondrial swelling has been associated with elevated levels of Ca2+ as well, that is to say protective effects of S-15176 were not only related to its antioxidant properties\textsuperscript{40}. S-15176 has drawn attention with different functions in some other ways. Hamdan et al.\textsuperscript{25} have investigated the effect of S-15176 on mitochondrial uptake. They have reported that S-15176 inhibits ATP synthase inhibition\textsuperscript{41}. In an other study, Albengres et al.\textsuperscript{38} have shown that S-15176 prevents the opening of PTP totally by inhibiting adenine nucleotide translocase which regulates the exchange of ADP/ATP. Thus, Ca2+ won't be able to move out through PTP. It has been stated that S-15176 prevents the instability of the resting membrane potential and oxidation of NAD(P)H. Mitochondrial swelling has been associated with increased levels of Ca2+ as well, that is to say protective effects of S-15176 were not only related to its antioxidant properties\textsuperscript{40}. S-15176 has drawn attention with different functions in some other ways. Hamdan et al.\textsuperscript{25} have investigated the effect of S-15176 on mitochondrial uptake. They have reported that S-15176 inhibits ATP synthase inhibition\textsuperscript{41}. In an other study, Albengres et al.\textsuperscript{38} have shown that S-15176 prevents the opening of PTP totally by inhibiting adenine nucleotide translocase which regulates the exchange of ADP/ATP. Thus, Ca2+ won't be able to move out through PTP. It has been stated that S-15176 prevents the instability of the resting membrane potential and oxidation of NAD(P)H. Mitochondrial swelling has been associated with elevated levels of Ca2+ as well, that is to say protective effects of S-15176 were not only related to its antioxidant properties\textsuperscript{40}. In this study S-15176 has been proposed to be a more universal permeability transition inhibitor than Cyclosporine A or oligomycin as S-15176 was effective in suppressing the permeability transition and the subsequent cyt-c release induced by Ag(+)\textsuperscript{30}.

S-15176 also inhibits ATP synthase activity but considering the protective effects of S-15176, inhibition of PTP does not seem to be related to inhibition of ATP synthase activity. An increase in transmembrane potential, ATP matrix content or phosphate uptake could be the reason for the protective effect of ATP synthase inhibition\textsuperscript{39}. In an other study, Albengres et al.\textsuperscript{38} have shown that S-15176 prevents the opening of PTP totally by inhibiting adenine nucleotide translocase which regulates the exchange of ADP/ATP. Thus, Ca2+ won't be able to move out through PTP. It has been stated that S-15176 prevents the instability of the resting membrane potential and oxidation of NAD(P)H. Mitochondrial swelling has been associated with elevated levels of Ca2+ as well, that is to say protective effects of S-15176 were not only related to its antioxidant properties\textsuperscript{40}. S-15176 has drawn attention with different functions in some other ways. Hamdan et al.\textsuperscript{25} have investigated the effect of S-15176 on mitochondrial uptake. They have reported that S-15176 inhibits ATP synthase inhibition\textsuperscript{41}. In another study, Albengres et al.\textsuperscript{38} have shown that S-15176 prevents the opening of PTP totally by inhibiting adenine nucleotide translocase which regulates the exchange of ADP/ATP. Thus, Ca2+ won't be able to move out through PTP. It has been stated that S-15176 prevents the instability of the resting membrane potential and oxidation of NAD(P)H. Mitochondrial swelling has been associated with elevated levels of Ca2+ as well, that is to say protective effects of S-15176 were not only related to its antioxidant properties\textsuperscript{40}. S-15176 has drawn attention with different functions in some other ways. Hamdan et al.\textsuperscript{25} have investigated the effect of S-15176 on mitochondrial uptake. They have reported that S-15176 inhibits ATP synthase inhibition\textsuperscript{41}. In another study, Albengres et al.\textsuperscript{38} have shown that S-15176 prevents the opening of PTP totally by inhibiting adenine nucleotide translocase which regulates the exchange of ADP/ATP. Thus, Ca2+ won't be able to move out through PTP. It has been stated that S-15176 prevents the instability of the resting membrane potential and oxidation of NAD(P)H. Mitochondrial swelling has been associated with elevated levels of Ca2+ as well, that is to say protective effects of S-15176 were not only related to its antioxidant properties\textsuperscript{40}.

In the S-15176-treated third and seventh day groups, the numbers of apoptotic cells per unit area were found to be reduced compared to the trauma groups. This finding indicated that apoptotic cell death was significantly prevented by the S-15176. In this study, bax, cyt-c and caspase-9 immunopositive cell numbers were found to be significantly reduced compared to the trauma groups. These findings support the hypothesis that use of S-15176 as a Difumarate salt is able to prevent the expression of pro-apoptotic proteins, which could develop in the early stages of the mitochondrial apoptosis pathway.

In this study, after the evaluation of subject neurological functions, the average BBB values obtained from animals showed a significant increase in seventh day results of the S-15176 group compared to all the trauma groups. The locomotor abilities of the subjects of the S-15176-treated trauma groups were found to be increased compared to the subjects of the trauma groups. This finding showed that administration of S-15176 to trauma groups was able to contribute to the healing of neurological functions after SCI.

**CONCLUSION**

Since the first recorded use of S-15176 in an experimental model for SCI, morphological evaluation have revealed that it would prevent secondary injury in trauma groups. Here we suggest that S-15176 prevents the release of cyt-c from mitochondria by stabilizing MMP and inhibits apoptotic cell death via knockdown of caspase-9 expression. We have come to the conclusion that S-15176 should be considered as a neuroprotective agent. Therefore, future studies are highly necessary to better understand the impact of treatment strategies on outcomes in “real” patients.

**Acknowledgements**

This work was supported by Scientific Research Projects Coordination Unit of Istanbul University, project number UDP-18761.

**References**

1. Albengres E, Le Louët H, d’Athis P, Tillément JP : S15176 and S16950 interaction with Cyclosporin A antiproliferative effect on cultured human lymphocytes. Fundam Clin Pharmacol 15 : 41-46, 2001
2. Allen AR : Surgery of experimental lesion of spinal cord equivalent to crush injury of fracture dislocation of spinal column : a preliminary report. JAMA 57 : 877-880, 1911
3. Amar AP, Levy ML : Pathogenesis and pharmacological strategies for mitigating secondary damage in acute spinal cord injury. Neurosurgery 44 : 1027-1039; discussion 1039-1040, 1999
4. Basso DM, Beattie MS, Bresnahan JC : A sensitive and reliable locomotor rating scale for open field testing in rats. J Neurotrauma 12 : 1-21, 1995
5. Bernardi P : The permeability transition pore. Control points of a cyclosporin A-sensitive mitochondrial channel involved in cell death. Biochim Biophys Acta 1275 : 5-9, 1996
6. Bernardi P, Brokkenmeier KM, Pfeiffer DR : Recent progress on regulation of the mitochondrial permeability transition pore: a cyclosporin-sensitive pore in the inner mitochondrial membrane. J Bioenerg Biomembr 26 : 509-517, 1994
7. Brokkenmeier KM, Dempsey ME, Pfeiffer DR : Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria. J Biol Chem 264 : 7826-7830, 1989
8. Chávez E, Rodríguez JS, García G, García N, Correa F : Olmesartan strengthens the effect of cyclosporin A on mitochondrial permeability transition by inducing phosphate uptake. Cell Biol Int 29 : 551-558, 2005
9. Cheng H, Cao Y, Olson L : Spinal cord repair in adult paraplegic rats : partial restoration of hind limb function. Science 273 : 510-513, 1996
10. Crompton M : The mitochondrial permeability transition pore and its
role in cell death. Biochem J 341 (Pt 2) : 233-249, 1999

11. Crompton M, Costi A, Hayat L : Evidence for the presence of a revers-
ible Ca2+-dependent pore activated by oxidative stress in heart mito-
chondria. Biochem J 245 : 915-918, 1987

12. Crowe MJ, Bresnahan JC, Shuman SL, Masters JN, Beattie MS : Apo-
tosis and delayed degeneration after spinal cord injury in rats and mon-
keys. Nat Med 3 : 73-76, 1997

13. Dumont RJ, Okonkwo DO, Verma S, Hurlbert RJ, Boulos PT, Ellegala
DB, et al. : Acute spinal cord injury, part I: pathophysiological mecha-
nisms. Clin Neuropharmacol 24 : 254-264, 2001

14. Dumont RJ, Verma S, Okonkwo DO, Hurlbert RJ, Boulos PT, Ellegala
DB, et al. : Acute spinal cord injury, part II: contemporary pharma-
cotherapy. Clin Neuropharmacol 24 : 265-279, 2001

15. Elimiadi A, Jullien V, Tillement JP, Morin D : S-15176 inhibits mito-
chondrial permeability transition via a mechanism independent of its
antioxidant properties. Eur J Pharmacol 468 : 93-101, 2003

16. Elimiadi A, Sapena R, Setta A, Le Louet H, Tillement J, Morin D : At-
tenuation of liver normothermic ischemia–reperfusion injury by pres-
servation of mitochondrial functions with S-15176, a potent mito-
chondrial controlled permeability transition activator. Biochim Biophys
Acta 1409 : 182-190, 2000

17. Elimiadi A, Setta A, Morin D, Sapena R, Larchouë F, Cherrah Y, et al.
: Trimetazidine counteracts the hepatic injury associated with ischemia-
reperfusion by preserving mitochondrial function. J Pharmacol Exp
Ther 286 : 23-28, 1998

18. Fiskum G : Mitochondrial participation in ischemic and traumatic neu-
ral cell death. J Neurotrauma 17 : 843-855, 2000

19. Fournier N, Ducet G, Crevat A : Action of cyclosporine on mito-
chondrial calcium fluxes. J Bioenerg Biomembr 19 : 297-303, 1987

20. Friberg H, Ferrand-Drake M, Bengtsson E, Halestrap AP, Wiechot T :
Cyclosporin A, but not FK 506, protects mitochondria and neurons
against hypoglycemic damage and implicates the mitochondrial perme-
ability transition in cell death. J Neurosci 18 : 5151-5159, 1998

21. Geisler FH, Dorsey FC, Coleman WP : Recovery of motor function after
arterial spinal-cord injury—a randomized, placebo-controlled trial with
GM-1 ganglioside. N Engl J Med 324 : 1829-1838, 1991

22. Green DR, Reed JC : Mitochondria and apoptosis. Science 281 : 1309-
1312, 1998

23. Halestrap AP, Connern CP, Griffiths EI, Kerr PM : Cyclosporin A bind-
ing to mitochondrial cyclophilin inhibits the permeability transition
pore and protects hearts from ischaemia/reperfusion injury. Mol Cell
Biochem 174 : 167-172, 1997

24. Hamburger V : Cell death in the development of the lateral motor col-
mum of the chick embryo. J Comp Neurol 160 : 535-546, 1975

25. Hamdan M, Uren S, Le Louet H, Tillement JP, Morin D : Inhibition of
mitochondrial carnitine palmitoyltransferase-1 by a trimetazidine de-
rivative, S-15176. Pharmacol Res 44 : 99-104, 2001

26. Haug T, Mothes D, Goujon JM, Carriere JC, Carriere M, Le Moyec L, et al. :
Trimetazidine prevents renal injury in the isolated perfused pig kidney
exposed to prolonged cold ischemia. Transplantation 64 : 1082-
1086, 1997

27. Hu Y, Benedict MA, Ding L, Niteiz G : Role of cytochrome c and dATP/ATP hydrolysis in Apaf-1-mediated caspase-9 activation
and apoptosis. EMBO J 18 : 3586-3595, 1999

28. Joshi DC, Balokova JC : Determination of mitochondrial membrane
potential and reactive oxygen species in live rat cortical neurons. J Vis
Exp 23 : (51). Fisi : 2704, 2011

29. Kateh K, Itaka T, Katoh S, Hamada Y, Nakachi K, Sano T, et al. : Induc-
tion and its spread of apoptosis in rat spinal cord after mechanical trau-
ma. Neurosci Lett 216 : 9-12, 1996

30. Kawashima S, Yamamoto T, Horiuchi Y, Fujwara K, Gouda S, Yo-
shimura Y, et al. : S-15176 and its methylated derivative suppress the
Ca2+-insensitive mitochondrial permeability transition and subsequent
cytochrome c release induced by silver ion, and show weak protone-
phoric activity. Mol Cell Biochem 358 : 45-51, 2011

31. Keane RW, Krayelsih S, Lotocki G, Bethea JR, Kracowski S, Reed JC, et al. :
Apoptotic and anti-apoptotic mechanisms following spinal cord in-
jury. J Neuropathol Exp Neurol 60 : 422-429, 2001

32. Kluck RM, Bossy-Wetzel E, Green DR, Newman DD : The release of
cytochrome c from mitochondria: a primary site for Bcl-2 regulation of
apoptosis. Science 275 : 1132-1136, 1997

33. Kromer G, DallaPorta B, Resje-Rigon M : The mitochondrial death/
life regulator in apoptosis and necrosis. Annu Rev Physiol 60 : 619-642,
1998

34. Kromer G, Petit P, Zamzami N, Vaysseire JL, Mignotte B : The bio-
chemistry of programmed cell death. FASEB J 9 : 1277-1287, 1995

35. Liu XZ, Xu XM, Hu R, Du C, Zhang SX, McDonald JW, et al. : Neur-
onal and glial apoptosis after traumatic spinal cord injury. J Neurosci 17 :
5395-5406, 1997

36. Lu J, Ashwell KW, Waite P : Advances in secondary spinal cord injury :
role of apoptosis. Spine (Phila Pa 1976) 25 : 1859-1866, 2000

37. Ly JD, Grubbr DR, Lawen A : The mitochondrial membrane potential
deptapsim(m)) in apoptosis; an update. Apoptosis 8 : 115-128, 2003

38. Morin D, Papadopoulos V, Tillement JP : Prevention of cell damage in
ischemia : novel molecular targets in mitochondria. Expert Opin Ther
ap Target 6 : 315-334, 2002

39. Morin D, Zini R, Berdeaux A, Tillement JP : Effect of the mitochondrial
transition pore inhibitor, S-15176, on rat liver mitochondria : ATP syn-
thase modulation and mitochondrial uncoupling induction. Biochem
Pharmacol 72 : 911-918, 2006

40. Novgorodov SA, Guida Tl, Brierley GP, Pfeiffer DR : Magnesium ion
modulates the sensitivity of the mitochondrial permeability transition
pore to cyclosporin A and ADP. Arch Biochem Biophys 311 : 219-228,
1994

41. Rupp H, Zarin-Herzberg A, Maisch B : The use of partial fatty acid oxida-
tion inhibitors for metabolic therapy of angina pectoris and heart fail-
ure. Herz 27 : 621-636, 2002

42. Sayeed I, Parvez S, Wali R, Siemens D, Stein DG : Direct inhibition of the
mitochondrial permeability transition pore : a possible mechanism for
better neuroprotective effects of allopregnanolone over progesterone.
Brain Res 1263 : 165-173, 2005

43. Schwab ME, Bartholdi D : Degeneration and regeneration of axons in
the lesioned spinal cord. Physiol Rev 76 : 319-370, 1996

44. Setta A, Morin D, Larchouë F, Elimadi A, Cherrah Y, Tillement JP :
Trimetazidine ameliorates the hepatic injury associated with ischaemia-
reperfusion in rats. Pharmacol Res 39 : 211-216, 1999

45. Setta A, Zahiady M, Elimadi A, Sapena R, Abahad IA, Tillement J, et al. :
S-15176 reduces the hepatic injury in rats subjected to experimental
ischemia and reperfusion. Eur J Pharmacol 406 : 281-292, 2000

46. Shuman SL, Bresnahan JC, Beattie MS : Apoptosis of microglia and oli-
godendrocytes after spinal cord contusion in rats. J Neurosci Res 50 :
798-808, 1997

47. Sullivan PG, Thompson MB, Scheff SW : Cyclosporin A attenuates acute
mitochondrial dysfunction following traumatic brain injury. Exp Neurol
160 : 226-234, 1999

48. Tator CH : Biology of neurological recovery and functional restoration
after spinal cord injury. Neurosurgery 42 : 697-707; discussion 707-708,
1998

49. Tator CH, Fehlings MG : Review of the secondary injury theory of acute
spinal cord trauma with emphasis on vascular mechanisms. J Neuro-
surg 75 : 15-26, 1991

50. Tatton WG, Chalmers-Redman RM : Mitochondria in neurodegenera-
tive disorders: an opportunity for therapy? Ann Neurol 44 (3 Suppl 1) :
S134-S141, 1998

51. Tuncel M, Yıldırım A, Karaoğlan A, Akdemir O, Oztürk M : AR-

52. The Effects of Difumarate Salt S-15176 after SCI in Rats | H Erdoğan, et al.
A014418 as a glycogen synthase kinase-3 inhibitor: anti-apoptotic and therapeutic potential in experimental spinal cord injury. *Neurocirugia (Astur)* 24: 22-32, 2013

52. Tunçdemir M, Ozturk M: The effects of ACE inhibitor and angiotensin receptor blocker on clusterin and apoptosis in the kidney tissue of streptozotocin-diabetic rats. *J Mol Histol* 39: 605-616, 2008

53. Yılmaz MB, Tönge M, Emmez H, Kaymaz E, Kaymaz M: Neuroprotective effects of quetiapine on neuronal apoptosis following experimental transient focal cerebral ischemia in rats. *J Korean Neurosurg Soc* 54: 1-7, 2013

54. Yong C, Arnold PM, Zoubine MN, Citron BA, Watanabe I, Berman NE, et al.: Apoptosis in cellular compartments of rat spinal cord after severe contusion injury. *J Neurotrauma* 15: 459-472, 1998

55. Youdim MB, Bar Am O, Yoge-Falach M, Weinreb O, Maruyama W, Naoi M, et al.: Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition. *J Neurosci Res* 79: 172-179, 2005

56. Young W: Secondary injury mechanisms in acute spinal cord injury. *J Emerg Med 11 Suppl 1*: 13-22, 1993

57. Zoratti M, Szabó I: The mitochondrial permeability transition. *Biochim Biophys Acta* 1241: 139-176, 1995